A groundbreaking study spearheaded by researchers at McMaster University has confirmed that the widespread use of the inexpensive medication pantoprazole not only prevents life-threatening upper gastrointestinal (GI) bleeding in critically ill, mechanically ventilated patients but also yields significant cost savings for hospitals.

Published on December 1, 2025, in JAMA Network Open, this is the first research to specifically detail the economic benefits of prescribing this proton pump inhibitor in the Intensive Care Unit (ICU). Patients requiring mechanical ventilation are particularly vulnerable to stress-induced ulcers in the stomach, which can lead to serious GI bleeding, a complication known to extend hospital stays and substantially increase overall medical expenses.

The new findings provide a powerful economic complement to the clinical evidence established by the landmark Re-evaluating the Inhibition of Stress Erosions (REVISE) Trial, also led by McMaster.

The international REVISE Trial involved over 4,800 patients across 68 centers in eight countries and previously proved pantoprazole’s effectiveness in preventing bleeding. By demonstrating that this widely available medication is both clinically effective and economically advantageous, the researchers have provided a compelling case for its standard use. Using pantoprazole for prophylactic stress ulcer prevention can help reduce severe complications, shorten the length of stay for the sickest patients, and ultimately save hospitals thousands of dollars.

Read More